Market Overview

The ACE inhibitors drug market is predicted to develop at a compound annual growth rate (CAGR) of 5.92% from 2024 to 2033, when it is projected to reach USD 14.32 billion, based on an average growth pattern. The market is estimated to reach a value of USD 8.5 billion in 2024.

SOURCE: We Market Research

Angiotensin-converting enzyme (ACE) inhibitors are a class of medications commonly used to treat conditions such as hypertension, heart failure, and chronic kidney disease. They work by blocking the activity of the angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system. This system regulates blood pressure and fluid balance. By inhibiting ACE, these drugs reduce the production of angiotensin II, a potent vasoconstrictor, and decrease the secretion of aldosterone, leading to vasodilation and decreased fluid retention. As a result, ACE inhibitors help relax blood vessels, lower blood pressure, and improve cardiac function, making them valuable in managing cardiovascular and renal disorders.

The ACE inhibitors drug market is driven by several key factors. Firstly, the rising prevalence of cardiovascular diseases, hypertension, and chronic kidney disorders globally has increased the demand for effective pharmaceutical interventions. Additionally, the aging population contributes to a growing patient pool requiring cardiovascular care. The emphasis on preventive healthcare and awareness campaigns further fuels market growth. Advances in research and development, leading to the introduction of novel ACE inhibitors with enhanced efficacy and fewer side effects, also contribute to market expansion. Furthermore, the increasing healthcare expenditure and accessibility to medical services in developing regions amplify the market's potential, fostering continued innovation and market competitiveness.

 Market Scope

ACE inhibitors drug Industry: Dynamics & Restrains

Market Drivers

Clinical Effectiveness and Established Track Record - The clinical effectiveness and established track record of ACE inhibitors drive their prominence in the pharmaceutical market. With a well-documented history of efficacy and safety in managing hypertension and heart-related conditions, healthcare professionals often rely on these drugs as first-line treatments. Patients benefit from their proven ability to reduce blood pressure, mitigate cardiovascular risks, and improve outcomes. The familiarity and positive clinical experiences contribute to a high level of confidence among prescribers and patients, establishing ACE inhibitors as a trusted and widely prescribed class of medications for cardiovascular health.

Prevalence of Hypertension and Cardiovascular Diseases- The prevalence of hypertension and cardiovascular diseases significantly propels the ACE inhibitors drug market. As these health conditions continue to affect a substantial global population, there is a growing demand for effective antihypertensive medications. ACE inhibitors, renowned for their efficacy in managing hypertension and related cardiovascular issues, become pivotal in addressing this widespread health concern. The escalating number of individuals diagnosed with hypertension creates a sustained market need for medications that can effectively regulate blood pressure and improve cardiovascular outcomes. This high prevalence underscores the pivotal role ACE inhibitors play in meeting the therapeutic requirements of a large and expanding patient demographic.

Market restrains

Competition from Alternative Therapies- Competition from alternative therapies poses a constraint on the ACE inhibitors drug market. The availability of various antihypertensive medications, such as angiotensin II receptor blockers (ARBs), calcium channel blockers, and diuretics, presents physicians with diverse treatment options. Patient-specific factors and preferences, as well as considerations related to efficacy and side effects, contribute to the choice of alternative therapies over ACE inhibitors. The competitive landscape challenges the market share of ACE inhibitors, requiring pharmaceutical manufacturers to navigate a dynamic environment and address evolving preferences among healthcare providers and patients seeking tailored solutions for hypertension management.

We Market Research: ACE inhibitors drug Dashboard

Our marketing platform has an extensive dashboard that gives customers insightful information about market changes over time. A screenshot of our dashboard is provided below, and unique PDF login credentials will be sent to enable access to this informative resource.

ACE inhibitors drug Segmentation

Market- By Product Type Analysis

By Product Type, the ACE inhibitors drug Market is Categories into Phosphonate-Containing Agents, Dicarboxylate-Containing Agents, Sulfhydryl-Containing Agents. The Dicarboxylate-Containing Agents segment accounts for the largest share of around 41% in 2022.

Compared to other categories, DCAs like as lisinopril, ramipril, and enalapril have less side effects but still have a strong blood pressure-lowering impact. They are highly favored by both patients and physicians because of this ideal balance between comfort and effectiveness.

The following segments are part of an in-depth analysis of the global ACE inhibitors drug market:

ACE inhibitors drug Industry: Regional Analysis

North America Market Forecast

North America dominate the ACE inhibitors drug Market with the highest revenue generating market with share of more than 48%. One of the many factors propelling the ACE inhibitor market in North America is the rising incidence of cardiovascular diseases in the region. The favorable reimbursement regulations and the well-established healthcare system both contribute to the widespread use of ACE inhibitors. Big pharmaceutical companies in North America engage in active research and development, leading to the introduction of new drugs and maintaining the market's growth momentum.

Europe Market Statistics

Europe is the second-largest market for ACE inhibitors drug. The aging population in Europe is driving the demand for ACE inhibitors since they are more at risk for cardiovascular problems. The strict regulatory environment in the area facilitates the creation, licensing, and marketing of drugs. Because of this, ACE inhibitors—which are crucial for treating ailments including heart failure and hypertension—find a strong market in Europe. The need for these drugs is fueled in part by the focus on patient outcomes and healthcare quality.

Asia Pacific Market Forecasts

Asia Pacific is expected to be the fastest-growing market for ACE inhibitors drug during the forecast period. The market for ACE inhibitors is growing in the Asia-Pacific area for a number of reasons. The need for these medications is fueled by a growing prevalence of hypertension and related disorders as well as a growing awareness of cardiovascular diseases. Because of the region's expanding healthcare spending and developing healthcare infrastructure, which enhance accessibility, ACE inhibitors are a vital part of cardiovascular therapy. The changing lifestyle and changing demographics are contributing factors to the increase in cardiovascular disease cases.

 Key Market Players

The ACE inhibitors drug Market is dominated by a few large companies, such as

·         GlaxoSmithKline

·         Teva Pharmaceutical Industries Ltd.

·         Lupin Limited

·         Cipla

·         Torrent Pharmaceuticals Ltd.

·         Sun Pharmaceutical Industries Ltd.

·         Macleods Pharmaceuticals Limited

·         Zydus Cadila

·         Mylan

·         Sandoz

·         Accord Healthcare

·         Dr. Reddy's Laboratories Ltd.

·         Cadila Healthcare Limited

·         Novartis AG

·         Pfizer Inc.

·         Merck & Co.

·         AstraZeneca

·         Sanofi

·         Boehringer Ingelheim

·         Others

Recent Developments:

·         May 2021, Novartis declared that the FDA had approved Entresto, a novel ACE inhibitor medication, for the management of heart failure. It has been demonstrated that this medication lowers the risk of hospitalization and death in heart failure patients.

·         November 2020, The COVID-19 vaccine's 95% efficacy was revealed by Pfizer and BioNTech in their joint clinical study results. The creation of the COVID-19 vaccine has been a significant milestone for Pfizer, a prominent manufacturer of ACE inhibitors.